β-Thalassemias

N Engl J Med. 2021 Feb 25;384(8):727-743. doi: 10.1056/NEJMra2021838.
No abstract available

Publication types

  • Review

MeSH terms

  • Activin Receptors, Type II / therapeutic use
  • Erythrocyte Transfusion / adverse effects
  • Genetic Therapy
  • Genotype
  • Hematinics / therapeutic use
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Immunoglobulin Fc Fragments / therapeutic use
  • Iron Overload / etiology
  • Phenotype
  • Recombinant Fusion Proteins / therapeutic use
  • beta-Thalassemia* / complications
  • beta-Thalassemia* / diagnosis
  • beta-Thalassemia* / genetics
  • beta-Thalassemia* / therapy

Substances

  • Hematinics
  • Immunoglobulin Fc Fragments
  • Recombinant Fusion Proteins
  • luspatercept
  • Activin Receptors, Type II